AIP
CRVS icon

Ameritas Investment Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

Ameritas Investment Partners’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.5K Sell
4,748
-600
-11% -$9.57K ﹤0.01% 1890
2025
Q4 		$41.2K Hold
5,348
– – ﹤0.01% 2254
2025
Q3 		$39.4K Hold
5,348
– – ﹤0.01% 2313
2025
Q2 		$21.4K Buy
+5,348
New +$19.5K ﹤0.01% 2622
2019
Q2 		– Sell
-1,216
Closed -$5K – 3059
2019
Q1 		$5K Hold
1,216
– – ﹤0.01% 2850
2018
Q4 		$4K Hold
1,216
– – ﹤0.01% 2883
2018
Q3 		$10K Hold
1,216
– – ﹤0.01% 2825
2018
Q2 		$13K Buy
1,216
+957
+369% +$10.7K ﹤0.01% 2728
2018
Q1 		$3K Hold
259
– – ﹤0.01% 2899
2017
Q4 		$3K Hold
259
– – ﹤0.01% 2908
2017
Q3 		$4K Hold
259
– – ﹤0.01% 2932
2017
Q2 		$3K Hold
259
– – ﹤0.01% 2959
2017
Q1 		$5K Buy
+259
New +$4.06K ﹤0.01% 2833

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ameritas Investment Partners's CRVS Position: Q1 2026 in Review

Ameritas Investment Partners reduced its Corvus Pharmaceuticals (CRVS) stake by 11% in Q1 2026, selling an estimated $9.57K and leaving 4,748 shares worth $69.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1890.

Ameritas Investment Partners first reported a position in CRVS in Q1 2017 and has held it in 13 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Ameritas Investment Partners held 4,748 shares of Corvus Pharmaceuticals worth $69.5K as of Q1 2026.
  • Ameritas Investment Partners sold 600 Corvus Pharmaceuticals shares in Q1 2026, an estimated $9.57K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1890 holding.
  • Ameritas Investment Partners first reported a position in Corvus Pharmaceuticals in Q1 2017 and has held it in 13 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.